BI's Pradaxa antidote progresses

Share this article:

Boehringer Ingelheim has inched closer to a Pradaxa antidote. The company announced Wednesday that it is set to launch its first-ever test among patients. The blood drug antidote, called idarucizumab, has been tested in healthy patients, and this latest test will involve emergency rooms in 35 countries.

Lack of an antidote is a concern with oral anti-coagulants, which include BI's Pradaxa as well as the BMS/Pfizer treatment Eliquis and Janssen's Xarelto. There is one exception: standby warfarin which, as MedPage's editor-in-chief noted in an April piece, is reversible.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.